DOI: 10.1128/AAC.00313-18
Article Figures & Data
Tables
- TABLE 1
Antimicrobial activity of plazomicin tested against 4,825 clinical isolates collected in 70 U.S. hospitals during 2014 to 2015
Organism or group (no. of isolates)a No. (cumulative %) of isolates at MIC (μg/ml) of: MIC50 (μg/ml) MIC90 (μg/ml) ≤0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 Enterobacteriaceae (4,362) 25 (0.6) 308 (7.6) 971 (29.9) 1,764 (70.3) 822 (89.2) 317 (96.4) 121 (99.2) 13 (99.5) 11 (99.8) 2 (99.8) 3 (99.9) 1 (99.9) 4 (100.0) 0.5 2 Klebsiella pneumoniae (1,506) 18 (1.2) 246 (17.5) 621 (58.8) 580 (97.3) 34 (99.5) 4 (99.8) 1 (99.9) 0 (99.9) 0 (99.9) 0 (99.9) 0 (99.9) 1 (99.9) 1 (100.0) 0.25 0.5 Escherichia coli (1,346) 1 (0.1) 6 (0.5) 75 (6.1) 641 (53.7) 534 (93.4) 81 (99.4) 6 (99.9) 0 (99.9) 0 (99.9) 0 (99.9) 0 (99.9) 0 (99.9) 2 (100.0) 0.5 1 Klebsiella oxytoca (359) 2 (0.6) 17 (5.3) 92 (30.9) 214 (90.5) 27 (98.1) 4 (99.2) 1 (99.4) 0 (99.4) 0 (99.4) 0 (99.4) 1 (99.7) 0 (99.7) 1 (100.0) 0.5 0.5 Enterobacter cloacae species complex (104) 0 (0.0) 14 (13.5) 30 (42.3) 51 (91.3) 8 (99.0) 1 (100.0) 0.5 0.5 Enterobacter aerogenes (120) 2 (1.7) 6 (6.7) 41 (40.8) 53 (85.0) 16 (98.3) 1 (99.2) 1 (100.0) 0.5 1 Serratia marcescens (107) 0 (0.0) 1 (0.9) 5 (5.6) 37 (40.2) 52 (88.8) 9 (97.2) 3 (100.0) 1 2 Citrobacter freundii species complex (159) 0 (0.0) 5 (3.1) 42 (29.6) 91 (86.8) 18 (98.1) 2 (99.4) 1 (100.0) 0.5 1 Citrobacter koseri (145) 2 (1.4) 12 (9.7) 63 (53.1) 58 (93.1) 6 (97.2) 3 (99.3) 1 (100.0) 0.25 0.5 Morganella morganii (118) 0 (0.0) 7 (5.9) 31 (32.2) 38 (64.4) 31 (90.7) 6 (95.8) 2 (97.5) 2 (99.2) 1 (100.0) 2 4 Providencia spp. (158) 0 (0.0) 1 (0.6) 0 (0.6) 18 (12.0) 27 (29.1) 54 (63.3) 44 (91.1) 5 (94.3) 8 (99.4) 0 (99.4) 1 (100.0) 2 4 Proteus mirabilis (124) 0 (0.0) 2 (1.6) 5 (5.6) 23 (24.2) 72 (82.3) 20 (98.4) 2 (100.0) 2 4 Proteus vulgaris group (116) 0 (0.0) 9 (7.8) 46 (47.4) 48 (88.8) 12 (99.1) 0 (99.1) 1 (100.0) 2 4 Pseudomonas aeruginosa (103) 0 (0.0) 1 (1.0) 3 (3.9) 1 (4.9) 3 (7.8) 17 (24.3) 49 (71.8) 17 (88.3) 7 (95.1) 4 (99.0) 0 (99.0) 0 (99.0) 1 (100.0) 4 16 Acinetobacter spp. (95) 1 (1.1) 0 (1.1) 7 (8.4) 14 (23.2) 17 (41.1) 25 (67.4) 7 (74.7) 11 (86.3) 4 (90.5) 4 (94.7) 1 (95.8) 0 (95.8) 4 (100.0) 2 16 Coagulase-negative staphylococci (72) 17 (23.6) 21 (52.8) 26 (88.9) 8 (100.0) 0.12 0.5 Staphylococcus aureus (69) 0 (0.0) 14 (20.3) 51 (94.2) 2 (97.1) 2 (100.0) 0.5 0.5 MRSA (30) 0 (0.0) 9 (30.0) 18 (90.0) 2 (96.7) 1 (100.0) 0.5 0.5 Streptococcus pneumoniae (66) 0 (0.0) 4 (6.1) 32 (54.5) 30 (100.0) 32 64 Enterococcus spp. (58) 0 (0.0) 1 (1.7) 8 (15.5) 7 (27.6) 9 (43.1) 5 (51.7) 8 (65.5) 16 (93.1) 4 (100.0) 16 64 ↵a MRSA, methicillin-resistant S. aureus.
- TABLE 2
Activities of plazomicin and comparator agents tested against Enterobacteriaceae isolates
Organism group (no. of isolates tested) and antimicrobial agent MIC50 (μg/ml) MIC90 (μg/ml) MIC range (μg/ml) % S using CLSI breakpointsa % S using EUCAST breakpointsa Enterobacteriaceae (4,362) Plazomicin 0.5 2 ≤0.06–>128 Amikacin 1 4 ≤0.25–>32 98.9 98.0 Gentamicin 0.5 4 ≤0.06–>8 90.3 89.2 Tobramycin 0.5 4 ≤0.12–>8 90.3 87.1 Ceftazidime 0.12 16 ≤0.015–>32 87.9 85.4 Meropenem 0.03 0.06 ≤0.015–>32 97.6 97.9 Piperacillin-tazobactam 2 16 ≤0.5–>64 92.0 89.2 Colistin ≤0.5 >8 ≤0.5–>8 84.0 Tigecycline 0.25 1 ≤0.06–4 99.0b 95.7 Levofloxacin ≤0.12 >4 ≤0.12–>4 82.9 79.5 CRE (97) Plazomicin 0.5 1 ≤0.06–>128 Amikacin 16 32 0.5–>32 64.9 46.4 Gentamicin 2 >8 0.12–>8 56.7 50.5 Tobramycin >8 >8 0.12–>8 13.4 11.3 Ceftazidime >32 >32 16–>32 0.0 0.0 Meropenem 16 >32 1–>32 2.1 7.2 Piperacillin-tazobactam >64 >64 32–>64 0.0 0.0 Colistin ≤0.5 >8 ≤0.5–>8 78.1 Tigecycline 0.5 1 0.12–2 100.0b 94.8 Levofloxacin >4 >4 ≤0.12–>4 18.6 11.3 Isolates carrying blaKPC genes (87) Plazomicin 0.25 1 ≤0.06–>128 Amikacin 16 32 0.5–>32 63.2 42.5 Gentamicin 4 >8 0.12–>8 55.2 48.3 Tobramycin >8 >8 0.12–>8 11.5 9.2 Ceftazidime >32 >32 4–>32 1.1 0.0 Meropenem 16 >32 0.5–>32 3.4 10.3 Piperacillin-tazobactam >64 >64 64–>64 0.0 0.0 Colistin ≤0.5 >8 ≤0.5–>8 78.2 Tigecycline 0.5 1 0.12–2 100.0b 96.6 Levofloxacin >4 >4 ≤0.12–>4 14.9 9.2 Carbapenemase-negative isolates (26) Plazomicin 0.5 1 0.12–2 Amikacin 4 16 0.5–32 92.3 84.6 Gentamicin 1 >8 0.25–>8 69.2 69.2 Tobramycin 2 >8 0.25–>8 57.7 50.0 Ceftazidime >32 >32 0.25–>32 19.2 15.4 Meropenem 2 32 0.03–32 23.1 53.8 Piperacillin-tazobactam >64 >64 1–>64 19.2 15.4 Colistin ≤0.5 >8 ≤0.5–>8 75.0 Tigecycline 0.5 2 0.06–2 100.0 88.5 Levofloxacin 2 >4 ≤0.12–>4 50.0 34.6 - TABLE 3
Activities of plazomicin and comparator aminoglycosides against phenotypes and genotypes of Enterobacteriaceae isolates and other Gram-negative species
Organism phenotype or genotype Source of breakpoint criteria for aminoglycoside resistance (no. of isolates)a % of isolates inhibited by plazomicin at ≤4 μg/ml MIC50/MIC90 (μg/ml) Plazomicin Amikacin Gentamicin Tobramycin Enterobacteriaceae NA (4,362) 99.2 0.5/2 1/4 0.5/4 0.5/4 Amikacin resistant CLSI (14) 64.3 1/>128 >32/>32 >8/>8 >8/>8 EUCAST (50) 90.0 0.5/4 32/>32 2/>8 >8/>8 Gentamicin resistant CLSI (377) 96.6 0.5/2 2/8 >8/>8 >8/>8 EUCAST (424) 95.5 0.5/2 2/8 >8/>8 >8/>8 Tobramycin resistant CLSI (292) 96.9 0.5/2 4/32 >8/>8 >8/>8 EUCAST (423) 96.5 0.5/2 4/32 >8/>8 >8/>8 CRE NA (97) 99.0 0.5/1 16/32 2/>8 >8/>8 CPE (all carrying blaKPC) NA (87) 98.9 0.25/1 16/32 4/>8 >8/>8 Carbapenemase negative NA (26) 100.0 0.5/1 4/16 1/>8 2/>8 Pseudomonas aeruginosa NA (103) 71.8 4/16 2/8 2/8 0.5/1 Acinetobacter baumannii NA (99) 65.2 2/32 4/>32 1/>8 1/>8 ↵a NA, not applicable.
